The impact of biosimilars in the U.S. will be gradual. Drug-company investors should still be wary.
WSJ.com: Heard on the Street, Wall Street Journal: Markets: Heard on the Street
Thu, 09/03/2015 - 12:10pm
The impact of biosimilars in the U.S. will be gradual. Drug-company investors should still be wary.